Company
The Company
CellGenix Technologie Transfer GmbH is an innovative biopharmaceutical company headquartered in Freiburg, Germany. CellGenix, which was founded in 1994 as a spin-off of the University Medical Center Freiburg, currently has more than 50 employees. CellGenix develops, manufactures and markets cell and protein therapeutics for cancer and orthopedic patients, as well as high-quality reagents for therapeutic ex vivo cell processing. The company owns Metreon Bioproducts GmbH, which was founded in 1996 and which is specialized on cell processing. CellGenix also owns shares in American Fluoroseal Cooperation (Afc) in Gaithersburg, Maryland (USA), and in CellPrep S.A. in Buenos Aires (Argentina).
CellGenix Main Building |
View on GMP Facility block |
R & D Labs |
Innovative research and development
Serum-free Chondrocyte Culture |
CellGenix's research focuses on stem cell therapy for the regeneration of tissues and organs, cancer immunotherapy and the development of GMP-grade ex vivo cell processing tools, like cytokines, serum-free media and closed kit systems. A patient-specific idiotype vaccine (IdioVax®) against Non-Hodgkin´s B-cell lymphoma is already in a Phase II clinical trial which is being conducted in collaboration with Freiburg's University Medical Center and the Center for Clinical Research. 
|
Cutting edge products and services
High Performance Cytokines |
Together with its distribution partners CellGenix markets a variety of superior products and services for clinical cell therapy applications: cord blood cell processing and banking, autologous chondrocyte transplantation as well as GMP-grade cytokines, serum-free media and kit systems for ex vivo cell processing. Additionally, we offer specialized contract manufacturing services. |
Safety and superior quality
Quality Control |
CellGenix's extensive experience has enabled the company to build up a strong portfolio of products in the field of GMP-compliant production of cell and protein therapeutics. Continuous interaction with various competent authorities assures compliance with highest quality standards in the fields of individual biopharmaceuticals and cell based medicinal products. Since the Fall 2001, with the expansion of its office and production complex near the Freiburg airport, CellGenix has at its disposal one of the most technologically advanced GMP facilities for the processing and manufacturing of individual cell and protein therapeutics.
|